Literature DB >> 17706748

Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients.

Krystyna Pawlak1, Dariusz Pawlak, Michal Myśliwiec.   

Abstract

INTRODUCTION: Matrix metalloproteinases (MMPs), their tissue inhibitors (TIMPs) system, and fibrinolytic system, have been implicated as important factors in atherosclerosis and vascular remodeling. However, no data are yet available on the associations between these two systems in relation to carotid atherosclerosis in hemodialysis (HD) patients.
MATERIAL AND METHODS: We compared plasma levels of MMP-2, MMP-9, TIMP-1, TIMP-2; the parameters of fibrinolytic system: tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPAR) and its soluble receptor (suPAR), plasminogen activator inhibitor-1 (PAI-1), plasmin-alpha2-antiplasmin (PAP) complexes; high sensitivity C-reactive protein (hs CRP) as a marker of inflammation and a surrogate of atherosclerotic disease-intima media thickness (IMT) in HD patients and in healthy controls.
RESULTS: The values of the uPA, suPAR, PAP, MMP-2, TIMPs, hs CRP and IMT in the patients significantly exceeded those in controls. The concentrations of MMP-9, tPA and PAI-1 were similar in both investigated groups. uPA, uPAR and PAP were positively associated with MMP-2/TIMPs system; all mentioned above parameters (except TIMP-2) and hsCRP were associated with IMT. Multivariate analysis showed that uPA, MMP-2 and age were the strong independent variables linked to IMT values in HD patients.
CONCLUSIONS: The patients on haemodialysis treatment have evidence of disordered fibrinolysis/proteolysis balance in the plasma, independently associated with IMT on multivariate analysis. These data suggest the importance of uPA and MMP-2 levels in the developing of atherosclerosis in these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17706748     DOI: 10.1016/j.thromres.2007.06.008

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  9 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 2.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 3.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

Review 4.  The Association of Matrix Metalloproteinases with Chronic Kidney Disease and Peripheral Vascular Disease: A Light at the End of the Tunnel?

Authors:  Michele Provenzano; Michele Andreucci; Carlo Garofalo; Teresa Faga; Ashour Michael; Nicola Ielapi; Raffaele Grande; Paolo Sapienza; Stefano de Franciscis; Pasquale Mastroroberto; Raffaele Serra
Journal:  Biomolecules       Date:  2020-01-17

5.  Reduced Expression of Urokinase Plasminogen Activator in Brown Adipose Tissue of Obese Mouse Models.

Authors:  Chung-Ze Wu; Li-Chien Chang; Chao-Wen Cheng; Te-Chao Fang; Yuh-Feng Lin; Dee Pei; Jin-Shuen Chen
Journal:  Int J Mol Sci       Date:  2021-03-26       Impact factor: 5.923

Review 6.  Matrix Metalloproteinases and Subclinical Atherosclerosis in Chronic Kidney Disease: A Systematic Review.

Authors:  Andreas Kousios; Panayiotis Kouis; Andrie G Panayiotou
Journal:  Int J Nephrol       Date:  2016-03-02

7.  The effect of antihypertensive treatment on arterial stiffness and serum concentration of selected matrix metalloproteinases.

Authors:  Marek Rajzer; Wiktoria Wojciechowska; Tomasz Kameczura; Agnieszka Olszanecka; Danuta Fedak; Michał Terlecki; Kalina Kawecka-Jaszcz; Danuta Czarnecka
Journal:  Arch Med Sci       Date:  2016-03-23       Impact factor: 3.318

8.  Local Production of Soluble Urokinase Plasminogen Activator Receptor and Plasminogen Activator Inhibitor-1 in the Coronary Circulation Is Associated With Coronary Endothelial Dysfunction in Humans.

Authors:  Michel T Corban; Abhiram Prasad; Lisa Nesbitt; Darrell Loeffler; Joerg Herrmann; Lilach O Lerman; Amir Lerman
Journal:  J Am Heart Assoc       Date:  2018-08-07       Impact factor: 5.501

Review 9.  The Role of Prognostic and Predictive Biomarkers for Assessing Cardiovascular Risk in Chronic Kidney Disease Patients.

Authors:  Michele Provenzano; Michele Andreucci; Luca De Nicola; Carlo Garofalo; Yuri Battaglia; Silvio Borrelli; Ida Gagliardi; Teresa Faga; Ashour Michael; Pasquale Mastroroberto; Giuseppe Filiberto Serraino; Noemi Licastro; Nicola Ielapi; Raffaele Serra
Journal:  Biomed Res Int       Date:  2020-10-08       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.